DATATOP: A decade of neuroprotective inquiry

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Shoulson, Ira ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; LEVODOPA; SELEGILINE;

CLINICAL RESEARCH; COGNITION; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; MORTALITY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031711714     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440724     Document Type: Conference Paper

References (28)

1. Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in PD. New York: Academic Press, 1996
2. Bar PR, Beal MF, eds. Neuroprotection in CNS diseases. New York: Marcel Dekker, 1997
3. Parkinson Study Group. DATATOP: A multi-center controlled clinical trial in early PD. Arch Neurol 1989;46:1052-1060
4. Shoulson I. Protective therapy for PD. In: Koller WC, Paulson G, eds. Therapy of PD. New York: Marcel Dekker, 1990:357-358
5. Goetz CG, Tanner CM, Shannon KM. Progression of PD without levodopa. Neurology 1987;37:695-698
6. Parkinson Study Group. Effect of deprenyl on the progression of disability in early PD. N Engl J Med 1989;321:1364-1371
7. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of PD. Science 1989;245:519-522
8. Parkinson Srudy Group. Effects of tocopherol and deprenyl on the progression of disability in early PD. N Engl J Med 1993; 328:176-183
9. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on PD in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
10. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on PD in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45
11. Kieburtz K, McDermott M, Como P, et al., and the Parkinson Study Group. The effect of deprenyl and tocopherol on cognitive performance in early untreated PD. Neurology 1994;44: 1756-1759
12. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented PD patients. Neurology 1998;50:1327-1331
13. Panisset M. Siderowf A, McDermott M, Kieburtz K, Friedman J, Growdon J and the Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort [abstract]. Mov Disord 1997;12:836
14. Giladi N, McDermott M, Fahn S, Przedborski S, and the Parkinson Study Group. Freezing of gait in PD [abstract]. Mov Disord 1996;11(Suppl 1):167
15. Schulzer M, Mak E, Calne DB. The antiparkinsonian efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798
16. Ward CD. Does selegiline delay progression of PD? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220
17. Parkinson Study Group. Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects [abstract]. Mov Disord 1997;12: 838
18. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43: 318-325
19. National Center for Health Statistics. Vital statistics of the United States, 1991. Vol 11. Mortality, part A. DHHS publication no. (PHS) 96-1101. Washington, DC: Public Health Service, 1996
20. PD Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild PD: three year interim report. BMJ 1993;307:469-472
21. Lees AJ, for the PD Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild PD. BMJ 1995;311:1602-1607
22. Olanow CW, Godbold JM, Koller W. Patients taking selegiline may have received more levodopa than necessary. BMJ 1996; 213:702-703
23. Birkmayer W, Knoll J, Riederer P, Youdim MB.(-)-Deprenyl leads to prolongation of L-dopa efficacy in PD. Mod Probl Pharmacopsychiatry 1983;19:170-176
24. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in PD: a longterm study. J Neural Transm 1985;64:113-127
25. LeWitt P, Oakes D, Cui L, and the Parkinson Study Group. The need for levodopa as an end point of PD progression in a clinical trial of selegiline and α-tocopherol. Mov Disord 1997; 12:183-189
26. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on PD. Arch Neurol 1995;52:237-245
27. 123I] β-CIT striatal uptake correlates with symptom severity in PD. Ann Neurol 1995;38:589-598
28. 18F] dopa-PET and clinical study of the rate of progression of PD. Brain 1996;119: 585-591